[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545847":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":30,"collaborators":20,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":20,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":20,"enrollmentInfo":40,"targetDuration":20,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":20,"overallStatus":49,"whyStopped":20,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":20},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mHSPC-PSMA","EXPERIMENTAL","Patients with mHSPC who will receive pre-therapeutic PSMA PET\u002FCT and post-therapeutic PSMA PET\u002FCT after three-month novel endocrine therapy.",[13],"Diagnostic Test: PSMA PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","PSMA PET\u002FCT","pre-therapeutic PSMA PET\u002FCT and post-therapeutic PSMA PET\u002FCT after three-month novel endocrine therapy.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Xuhe Liao, Dr","CONTACT","0086-10-83575252","liaoxuhe@bjmu.edu.cn",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Hongwei Sun, Dr","lxhxixi@163.com",{"type":31,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100545847","exploration-of-the-value-of-psma-petct-in-dynamic-monitoring-of-the-efficacy-of-novel-endocrine-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-100545847",false,"NCT06387238","Exploration of the Value of PSMA PET\u002FCT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer","Inclusion Criteria:\n\n* Prostate cancer patients confirmed to have metastasis by PSMA PET\u002FCT before new endocrine therapy.\n\n  * Those who have not undergone androgen deprivation treatment in the past, or have currently received androgen deprivation treatment for no more than 120 days without progress, or have received androgen deprivation treatment in the past (treatment time less than 24 months and no progress within 12 months after completion).\n\n    * Patients with KPS score ≥ 50 (ECOG\u002FWHO equivalent).\n\n      * Patient age\\>18 years old.\n\nExclusion Criteria:\n\nPatients who cannot understand and voluntarily participate in this trial, donnot sign an informed consent form, and aren't able to cooperate independently in completing the examination.","MALE","18 Years",{"count":41,"type":42},150,"ESTIMATED","INTERVENTIONAL",[45],"NA","1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis.\n2. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of PSMA PET\u002FCT imaging, pre-treatment gene status, PSA, GS\u002FISUP and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis.",[48],"Prostate Adenocarcinoma","NOT_YET_RECRUITING","2024-04-23",{"date":52,"type":53},"2024-04-29","ACTUAL",{"date":55,"type":42},"2024-05-01",{"date":57,"type":42},"2026-06-30",{"name":5,"class":6}]